Not recruiting yet
VALSE: Integration of Neuromodulation and Exoskeleton Systems for Mobility in Individuals With Chronic Spinal Cord Injury
NCT07745686 · Ecole Polytechnique Fédérale de Lausanne · Updated 4 Aug 2026
- What is being tested
- TWIICE Rise 1.0 robotic exoskeleton combined with epidural electrical stimulation (EES)
- For
- Spinal Cord Injury
- Kind of study
- Tests a treatment or device on volunteers. No drug phase (a device or procedure study).
- Who can join
- Ages 18 years and older. About 12 people. The full rules are on the registry page.
- Where
- Switzerland
- When
- Starts or started 15 Sept 2026, ends Sept 2028. Registered 4 Aug 2026.
- Results
- None posted yet.
In the researchers' words
The purpose of this clinical study is to evaluate the preliminary safety and feasibility of using the VALSE system, which combines spinal cord stimulation with the TWIICE robotic exoskeleton, to support motor recovery and reduce reliance on laboratory-based equipment during rehabilitation in participants with traumatic spinal cord injury. The TWIICE exoskeleton is integrated through the NR system, a platform developed by EPFL. The goal is to assess the clinical safety and practical application of this combined neuroprosthetic approach in a small number of participants, in order to guide future refinements of the device and protocol, support the development of scalable interventions integrating spinal stimulation with robotic assistance, and inform strategies for delivering rehabilitation in more accessible, real-world environments.
Sites
- Centre Hospitalier Universitaire Vaudois (CHUV)Lausanne, Canton of Vaud, Switzerland